Alterations in this pathway, particularly PTEN inactivation, have been associated with resistance to the therapy of EGFR-tyrosine kinase inhibitor and results in lower survival in NSCLC patients [15]. The gene discussed is PTEN; the disease is non-small cell lung carcinoma.